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ABSTRACT 
THE INFLUENCE OF A SINGLE NUCLEOTIDE POLYMORPHISM IN THE MATRIX 
METALLOPROTEINASE-1 PROMOTER ON GLIOMA BIOLOGY 
Jessica McCready 
A dissertation submitted in partial fulfillment of the requirements for ,the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2006 
Director: Helen L. Fillmore, Ph.D. Assistant Professor Department of Neurosurgery, 
Adjunct Assistant Professor Department of Anatomy and Neurobiology 
Glioblastomas are an incurable type of brain tumor with a mean survival time of 
9-12 months following diagnosis. One of the reasons for this poor prognosis is the 
ability of tumor cells to invade the surrounding normal brain tissue. Enzymes 
responsible for this invasive nature include the matrix metalloproteinase family. MMP- 
1 is a member of this family which has been well studied in many types of invasive 
,tumors, with gliomas being an exception. We studied a single nucleotide 
polymorphism (SNP) in the MMP-1 promoter that may influence glioma biology. This 
SNP consists of the presence (2G) or absence (1G) of a guanine nucleotide at position 
-1607. The additional guanine nucleotide creates a binding site for ETS transcription 
factors and combined with the AP-1 binding site at position -1602 creates a Ras 
Responsive Element. We determined that the distribution of the MMP-1 genotype 
differed significantly between the healthy population and the glioblastoma patient 
population, with the 2G/2G genotype more prevalent in the glioblastoma patients. In 
addition, MMP-1 mRNA and protein examined in a select group of patient tissue had 
significantly higher levels when compared to normal brain controls, however, there was 
no correlation with genotype. Promoter reporter assays indicated that the 2G promoter 
was approximately three times more active than the 1G promoter in three different 
glioma cell lines. 
We investigated potential signaling mechanisms responsible for increases in 
MMP-1 transcription due to the presence of the RAS responsive element. Treatment 
of glioma cell lines with hepatocyte growth factorlscatter factor (HGFISF) led to 
significant increases in MMP-1 transcription, via the MAP kinase ERK pathway. AP-1 
transcription factor proteins, cJun and cFos were increased in response to HGF 
treatment but not Ets-1 and ETV-1. HGFISF treatment of glioma cell lines differing in 
their MMP-1 genotype affected binding of ETS and AP-1 proteins to the endogenous 
MMP-1 distal promoter. Using chromatin immunoprecipitation assays, we identified 
these differentially DNA-bound AP-1 and ETS proteins. 
The data presented indicate that the MMP-1 SNP (-1607) is important in glioma 
biology and may contribute to tumor function and future investigations into its role in 
glioma biology is warranted. 
Chapter 1 
Introduction 
1.1 Brain Tumors 
1.1.1 Overview of Brain Tumors 
This section will present a general overview of adult cancers, with a focus on 
gliomas, which account for approximately 86% of all malignant brain tumors. These 
include the astrocytoma, oligodendroglioma and glioblastoma. Malignant brain tumors 
make up 2% of all cancers in adults. This number is much higher for children as brain 
tumors are the second most common cancer and the most common solid tumor in 
childhood1. The incidences of brain tumors in both children under the age of 14 and in 
the elderly over the age of 702 are increasing and unfortunately these tumors, in most 
cases, remain incurable. 
In the general population of the United States, gliomas occur at a rate of 5-10 
per 100,000~. The incidence of gliomas increases, as in other cancers, in individuals 
older than 30 years of age. In general, males are more likely than females to have a 
brain tumor, with a male to female ratio of 1.5:1. Most brain tumors occur in the 
supratentorial region of the brain, in the frontal, temporal or parietal lobes, specifically1. 
Currently, little is known about the risk factors for gliomas. Many studies have been 
conducted, investigating such items as cell phones or head trauma for possible roles in 
the etiology of brain tumors, but none has been found to consistently associate with 
their incidence. Gliomas are thought to arise as a result of an accumulation of genetic 
alterations resulting in the ability of the cells to escape checkpoints designed to prevent 
uncontrolled cell growth. Therefore any agent that damages DNA, such as a chemical, 
physical or biological agent, can be considered to be a neurocarcinogen. One 
environmental agent that has been associated with increases in brain tumors in adults 
is ionizing radiation used as a treatment for childhood tumors and leukemia'. 

























































































































































Appendix 1.i DNA-Protein Affinity Pull Down Assay Protocol 
This assay determines the ability of proteins to bind to a piece of DNA 
mimicking the MMP-1 promoter. Before beginning the assay we performed PCR to 
prepare the double stranded biotin labeled probe. The primer sequences were as 
follows: forward 5'- biotinCCCTCTTGAACTCACATGTTATG-3'; reverse 5'- 
GCGTCAAGACTGATATCT-TACTC-3'. The forward primer was aliquoted upon 
receipt from the company and only thawed one time. This ensured that each PCR 
began with a fresh aliquot of biotinylated primer. We used 100 ng of genomic DNA 
isolated from either T98 glioma cells (1G probe) or U251 glioma cells (2G probe). The 
PCR conditions were as follows: 0.6 pM each primer, 200 pM dNTPs, 1.5 mM MgCI2, 
1x PCR Buffer wlo MgCI2, 1 unit Platinum Taq in a total volume of 25 pL. The PCR 
annealing temperature was 62°C and there were a total of 35 cycles. The PCR product 
was run on a 2% agarose gel to ensure the expected size piece of 11 Obp. The product 
must be purified by ethanol precipitation and resuspended in 60pL of TE pH 8.0. The 
purified probe was run on an agarose gel to quantify the amount relative to the DNA 
ladder. Two rounds of PCR were necessary to obtain enough probe for the assay. 
2 x 1 o6 U251 cells were plated in 10 % DMEM. 24 hours post plating the cells 
were rinsed with PBS and starved from serum overnight. 30nglmL of HGF was added 
to 3 mLs of fresh serum free media the following morning. At the desired timepoint the 
media was removed from the plate, the plates were washed once with PBS and the 
cells were scraped to the bottom of the plate and transferred to an eppendorf tube with 
1.5 mL ice cold PBS. Samples were spun for 10 minutes at maximum speed in a table 
top centrifuge at 4" C. The cell pellet was either used immediately or frozen at -80°C 
for use in the future. Nuclei were extracted following the method described in chapter 
2 of this document and nuclear lysates were quantitated with the Coomassie Plus 
Protein Assay. 60-100 pg of nuclear protein was added to an eppendorf tube to a final 
volume of 500 pL Lysis Buffer (20 mM HEPES, 10% glycerol, 50mM KCL, 0.2 mM 
EDTA, 1.5 mM MgCI2, 20 pM ZnC12, 1 mM DTT, and 0.25% Triton X-100). Protease 
and phosphatase inhibitors were added just before use. Nuclear extract was 
precleared with 20 pL Streptavidin-Paramagentic particles (SA-PMP, Pierce) in a 
rotating wheel at 4°C. [The SA-PMPs must be washed three times with 1 mL lysis 
buffer and collected in a magnetic stand 15 minutes prior to use.] Following the pre- 
clearing step the SA-PMPs were recovered in a magnetic stand. 1pg of the 
biotinylated oligonucleotide and 4 pg testes DNA were added to the pre-cleared 
supernatant and allowed to rotate at 4°C for 30 minutes after which 20 pL of washed 
SA-PMPs was added and the samples continued rotating for 2 hours at 4°C. The SA- 
PMP-DNA complexes were washed three times with 1 mL lysis buffer. After each 
wash the supernatant was discarded. After the final wash, 20 pL of Laemmli Sample 
Buffer:BME (950:50) was added to each sample. The samples were boiled for 5 
minutes and loaded into a Tris-Gly Gel (Invitrogen). The gel was run at 125 V for two 
hours and transferred at 25 V for two hours. 
probe 1G 2G 
Appendix I.ii DNA-Protein Affinity Pull Down Assay cFos 
The AP-1 protein cFos is able to bind to a biotinylated probe mimicking the 2G 
promoter following HGFISF treatment for 5 hours. These results are in agreement with 
the ChlP assay that also indicated that cFos bound to the endogenous 2G promoter at 
5 hours. Results from the ChlP assay also suggest that cFos is bound to the 1G 
promoter. There is a slight band in both the 5 hour and 12 hour lane that may 
correspond to cFos bound to the 1G promoter. 
U87 T98 LN-Z308 
Labeled MMP-1 probe -I+ + + + +I I +  + + + + I  
10pgnuclearextract - + + + + - + + + + - + + + + 
1 Ox cold MMP-1 probe - - + - - - -  + - - - -  + - -  
10xcoldEts-lprobe - - - +  - - - - + - - - - + - 
cold NFkB pr 
Appendix I.iv Electromobility Shift Assay -- 1G probe 
We performed an EMSA with a double stranded radionucleotide labeled probe 
mimicking the distal 1G MMP-1 promoter to determine if there was a difference in the 
banding pattern between the 1G and the 2G promoter probes. The data seems to 
suggest that there are similar proteins bound to both promoters however further 
experiments would be needed to confirm this initial observation. 
Labeled MMP-1 probe I + + + + + + + I 
10pgnuclearextract - + + + + + + 
10x cold MMP-1 probe - - + - - - - 
10x cold NFkB probe - - - + -  - -  
Ets-1 Supershift - - - - + - 
Ets-2 Supershift - - - - - + - 
Rabbit IgG 
Appendix I.iii Electromobility Shift Assay - Supershift. 
We performed an EMSA with antibodies to both Ets-1 and Ets-2 to determine if these 
are possible proteins bound to a probe mimicking the distal 2G promoter. Neither 
antibody formed a complex with the DNA-probe complex as indicated by the lack of a 
supershift of the band shift. This does not rule out these proteins as candidates of 
proteins bound to the probe because it could be a limitation of the antibody that is 
interfering with the protein-DNA-probe complex formation. 
Appendix 1l.i Promoter Activation 1 G Promoter -/+ HGFISF 
We peformed a luciferase reporter assay with the full length MMP-1 1G promoter 
construct (obtained from Constance Brinckerhoff, PhD) to determine the response of 
the 1 G promter to HGFISF treatment in glioma cells. The 1 G promoter responds to the 
HGFISF beginning at approximately three hours and continues at least for 24 hours. It 
is not surprising that the 1G promoter responds to HGFISF since it contains many 
binding sites that may be responsive to the growth factor including the necessary ETS 
element located at position -87 in the proximal promoter. 
Appendix Il.ii Promoter Activation 2G Promoter -I+ HGFISF 
We peformed a luciferase reporter assay with the full length MMP-1 2G promoter 
construct (obtained from Constance Brinckerhoff, PhD) to determine the response of 
the 2G promter to HGFISF treatment in glioma cells. The peak of 2G promoter ac.tivity 
is 12 hours after HGFISF treatment but the promoter activity begins at three hours in 
response to the growth factor and continues for at least 24 hours. 
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